Drug Overview
Menveo (quadrivalent oligosaccharide diphtheria CRM-197 conjugate vaccine; GlaxoSmithKline) is a quadrivalent meningococcal glycoconjugate vaccine that uses CRM-197, a natural mutant of the diphtheria toxin, as well as an aluminum phosphate adjuvant. It is approved for the prevention of meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals aged two months to 55 years in both the US and EU.
A large patient population and broad serotype coverage will ensure Menveo continues to compete directly with Menactra (quadrivalent polysaccharide diphtheria toxoid conjugate vaccine; Sanofi), with Menveo’s sales gradually increasing at its rival’s expense. Menactra is expected to continue to dominate the US market, except in high-risk children aged younger than nine months, for whom Menveo is the only quadrivalent meningococcal conjugate vaccine approved in the country. Menactra covers the same serotypes as Menveo, and due to its earlier launch, Menactra will likely continue to dominate, as the vaccines are interchangeable from a clinical perspective.
However, Menveo will capture a greater proportion of EU market share because Menactra is not approved in this region, and Menveo was approved two years before its main rival, Nimenrix (quadrivalent polysaccharide tetanus toxoid conjugate vaccine; Pfizer). In the long term, GlaxoSmithKline intends to position its pipeline vaccine MenABCW-135Y (pentavalent meningococcal conjugate vaccine) as a successor to Menveo and Bexsero (multi component meningococcal serogroup B vaccine), although the combined vaccine’s launch is not expected until 2022 in the US and EU.
Menveo (quadrivalent oligosaccharide diphtheria CRM-197 conjugate vaccine; GlaxoSmithKline) is a quadrivalent meningococcal glycoconjugate vaccine that uses CRM-197, a natural mutant of the diphtheria toxin, as well as an aluminum phosphate adjuvant. It is approved for the prevention of meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals aged two months to 55 years in both the US and EU.
A large patient population and broad serotype coverage will ensure Menveo continues to compete directly with Menactra (quadrivalent polysaccharide diphtheria toxoid conjugate vaccine; Sanofi), with Menveo’s sales gradually increasing at its rival’s expense. Menactra is expected to continue to dominate the US market, except in high-risk children aged younger than nine months, for whom Menveo is the only quadrivalent meningococcal conjugate vaccine approved in the country. Menactra covers the same serotypes as Menveo, and due to its earlier launch, Menactra will likely continue to dominate, as the vaccines are interchangeable from a clinical perspective.
However, Menveo will capture a greater proportion of EU market share because Menactra is not approved in this region, and Menveo was approved two years before its main rival, Nimenrix (quadrivalent polysaccharide tetanus toxoid conjugate vaccine; Pfizer). In the long term, GlaxoSmithKline intends to position its pipeline vaccine MenABCW-135Y (pentavalent meningococcal conjugate vaccine) as a successor to Menveo and Bexsero (multi component meningococcal serogroup B vaccine), although the combined vaccine’s launch is not expected until 2022 in the US and EU.
Table of Contents
OVERVIEW- Drug Overview
- Product Profiles
- Menveo : Meningococcal vaccines
LIST OF TABLES
Table 1: Menveo drug profile
Table 2: Approval history of Menveo for meningococcal vaccination in the US and five major EU markets
Table 3: Late-phase trials of Menveo for meningococcal vaccination
Table 4: Menveo for meningococcal disease – SWOT analysis
